Radiotherapy Prolongs Survival of NSCLC Patients
By MedImaging International staff writers Posted on 07 Sep 2017 |
Metastatic non-small-cell lung cancer (mNSCLC) patients treated with a combined chemotherapy and radiation therapy (RT) regimen can live up to one year longer, according to a new study.
Researchers at Siena University Hospital (Italy), Bianchi-Melacrino-Morelli Hospital (Reggio, Italy) and other institutions conducted a retrospective analysis of 69 patients with unresectable, inoperable mNSCLC who received the mPEBev chemotherapy regimen, composed of fractionated cisplatin, oral etoposide, and bevacizumab, a monoclonal antibody that inhibits blood vessel growth in the tumor. Of these patients, 45 were also given palliative RT treatments to one or more metastatic sites.
A statistical analysis of the study results revealed a much longer median survival period of about 10 months (with the longest survival of over two years) in the group of patients who received RT, with no difference in progression-free survival. In particular, the patients survival correlated with the mPEBev regimen ability to induce the percentage of activated dendritic cells (DCs) and central-memory- T-cells (CD3, CD8+, CD45RA-, and CCR7+). The study was published on August 24, 2017, in Oncotarget.
“We found that radiotherapy, together with its direct cytolytic effect on tumor tissue, also elicits systemic immunological events, similarly to cancer vaccines,” said study co-author Professor Luigi Pirtoli, MD, director of radiation oncology at the University of Siena. “This response may result in the regression of distant metastases, known as the abscopal effect, as suggested by immunological mechanisms further investigated by our team in previous research.”
NSCLC is the most common type of lung cancer, and include squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Other subtypes, such as adenosquamous and sarcomatoid carcinoma, are less common. Patients in early stages of NSCLC can undergo lung lobectomy, but it is not performed on patients that have lung cancer that has already metastasized to other parts of the body.
Related Links:
Siena University Hospital
Bianchi-Melacrino-Morelli Hospital
Researchers at Siena University Hospital (Italy), Bianchi-Melacrino-Morelli Hospital (Reggio, Italy) and other institutions conducted a retrospective analysis of 69 patients with unresectable, inoperable mNSCLC who received the mPEBev chemotherapy regimen, composed of fractionated cisplatin, oral etoposide, and bevacizumab, a monoclonal antibody that inhibits blood vessel growth in the tumor. Of these patients, 45 were also given palliative RT treatments to one or more metastatic sites.
A statistical analysis of the study results revealed a much longer median survival period of about 10 months (with the longest survival of over two years) in the group of patients who received RT, with no difference in progression-free survival. In particular, the patients survival correlated with the mPEBev regimen ability to induce the percentage of activated dendritic cells (DCs) and central-memory- T-cells (CD3, CD8+, CD45RA-, and CCR7+). The study was published on August 24, 2017, in Oncotarget.
“We found that radiotherapy, together with its direct cytolytic effect on tumor tissue, also elicits systemic immunological events, similarly to cancer vaccines,” said study co-author Professor Luigi Pirtoli, MD, director of radiation oncology at the University of Siena. “This response may result in the regression of distant metastases, known as the abscopal effect, as suggested by immunological mechanisms further investigated by our team in previous research.”
NSCLC is the most common type of lung cancer, and include squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Other subtypes, such as adenosquamous and sarcomatoid carcinoma, are less common. Patients in early stages of NSCLC can undergo lung lobectomy, but it is not performed on patients that have lung cancer that has already metastasized to other parts of the body.
Related Links:
Siena University Hospital
Bianchi-Melacrino-Morelli Hospital
Latest Nuclear Medicine News
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure
- New PET Radiotracer Aids Early, Noninvasive Detection of Inflammatory Bowel Disease